We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Park Hotels (PK) Sheds Non-Core Assets Worth $166 Million
Read MoreHide Full Article
Park Hotels & Resorts Inc. (PK - Free Report) recently announced selling of three non-core assets for $166 million. The move comes as part of the company’s capital-recycling efforts, helping substantially lower the company’s leverage ahead of its proposed merger with Chesapeake Lodging Trust .
The assets sold off this time include three hotels. These comprise the 507-room Hilton Atlanta Airport in Atlanta, GA; the 317-room Hilton New Orleans Airport in New Orleans, LA; and the 274-room Embassy Suites Parsippany in Parsippany, NJ.
Situated in non-core airport and suburban markets, these hotels generated a combined 2018 RevPAR of $109. The figure is around 37% lower than that of Park’s 2018 portfolio average. Hence, there disposition seems a strategic fit.
In fact, Park Hotels is on track with its capital-recycling efforts, generating more than $750 million through sale of 18 non-core assets since its formation in 2017. The company is focused on enhancing its market position and this May, it announced the $2.7-billion acquisition of Chesapeake Lodging Trust.
The cash-and-stock transaction, expected to close in late third quarter or early fourth quarter this year, will help Park Hotels significantly boost its portfolio quality, increasing comparable RevPAR by nearly 4% to $182 and enhance the EBITDA margin. The buyout will provide immediate brand, operator as well as geographic diversification, while the combined entity will benefit from increasing scale, lowering cost of capital and combined synergies.
Park Hotels currently carries a Zacks Rank #3 (Hold). In the year-to-date period, shares of the company have underperformed the industry. While the stock has appreciated 4.3%, the industry has increased 19.5% during this period.
Host Hotels’ Zacks Consensus Estimate for 2019 funds from operations (FFO) per share moved 2.8% north to $1.82 in the past two months.
Lamar’s FFO per share estimates for the current year inched up 0.3% to $5.83 over the past month.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Park Hotels (PK) Sheds Non-Core Assets Worth $166 Million
Park Hotels & Resorts Inc. (PK - Free Report) recently announced selling of three non-core assets for $166 million. The move comes as part of the company’s capital-recycling efforts, helping substantially lower the company’s leverage ahead of its proposed merger with Chesapeake Lodging Trust .
The assets sold off this time include three hotels. These comprise the 507-room Hilton Atlanta Airport in Atlanta, GA; the 317-room Hilton New Orleans Airport in New Orleans, LA; and the 274-room Embassy Suites Parsippany in Parsippany, NJ.
Situated in non-core airport and suburban markets, these hotels generated a combined 2018 RevPAR of $109. The figure is around 37% lower than that of Park’s 2018 portfolio average. Hence, there disposition seems a strategic fit.
In fact, Park Hotels is on track with its capital-recycling efforts, generating more than $750 million through sale of 18 non-core assets since its formation in 2017. The company is focused on enhancing its market position and this May, it announced the $2.7-billion acquisition of Chesapeake Lodging Trust.
The cash-and-stock transaction, expected to close in late third quarter or early fourth quarter this year, will help Park Hotels significantly boost its portfolio quality, increasing comparable RevPAR by nearly 4% to $182 and enhance the EBITDA margin. The buyout will provide immediate brand, operator as well as geographic diversification, while the combined entity will benefit from increasing scale, lowering cost of capital and combined synergies.
Park Hotels currently carries a Zacks Rank #3 (Hold). In the year-to-date period, shares of the company have underperformed the industry. While the stock has appreciated 4.3%, the industry has increased 19.5% during this period.
Stocks to Consider
Some better-ranked stocks from the real-estate space include Host Hotels & Resorts, Inc. (HST - Free Report) and Lamar Advertising Company (LAMR - Free Report) , each carrying a Zacks Rank of 2 (Buy), at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Host Hotels’ Zacks Consensus Estimate for 2019 funds from operations (FFO) per share moved 2.8% north to $1.82 in the past two months.
Lamar’s FFO per share estimates for the current year inched up 0.3% to $5.83 over the past month.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>